Abstract
Recent data from randomized trials of high-dose chemotherapy as treatment for high-risk primary and metastatic breast cancer provide important information about the risks and benefits of this treatment approach. Further research through well-designed, hypothesis-oriented clinical trials is needed to establish the role of high-dose chemotherapy in a multimodality treatment approach. M. D. Anderson Cancer Center continues to conduct such research.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Suggested Readings
Antman K, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.
Bergh J. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proceedings of the American Society of Clinical Oncology 1999; 18: 3.
Bezwoda WR. Randomized, controlled trial of high dose chemotherapy (HDCNVp) versus standard dose (CAF) chemotherapy for high risk, surgically-treated, primary breast cancer. Proceedings of the American Society of Clinical Oncology 1999;18:Abstract 4.
Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–2489.
Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508.
Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205.
Hortobagyi GN. Evolving concepts in high-dose chemotherapy for breast cancer. ASCO Educational Book for Fall 1999.
Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225–233.
Lotz JP, Curé H, Janvier M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic breast cancer: results of the French Protocol Pegase 04. Proceedings of the American Society of Clinical Oncology 1999;18:Abstract 161.
Peters WP. High-dose chemotherapy and stem-cell support for primary and metastatic breast cancer. ASCO Educational Book for Fall 1999.
Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proceedings of the American Society of Clinical Oncology 1996;Abstract 149.
Peters WP, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proceedings of the American Society of Clinical Oncology 1999;18:Abstract 2.
Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171–3177.
Rizzieri DA, Vredenburgh JJ, Jones R, et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999; 17: 3064–3074.
Rodenhuis S, Botenbal M, Beex LVAM, et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proceedings of the American Society of Clinical Oncology 2000;19:Abstract 286.
Rodenhuis S, Richel DJ, van der Wall E, et al. Randomized trial of high-dose chemotherapy and hemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515–521.
Stadtmauer EA, O’Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069 1076.
Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral blood progenitor cell transplantation for poor-risk patients with metastatic breast cancer. J Clin On col 1998; 16: 986–993.
Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000; 355: 999–1003.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ueno, N.T., Champlin, R.E. (2001). High-Dose Chemotherapy as Treatment for High-Risk Primary and Metastatic Breast Cancer. In: Hunt, K.K., Robb, G.L., Strom, E.A., Ueno, N.T. (eds) Breast Cancer. M. D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/978-0-387-21842-7_12
Download citation
DOI: https://doi.org/10.1007/978-0-387-21842-7_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95190-4
Online ISBN: 978-0-387-21842-7
eBook Packages: Springer Book Archive